Compare PRSO & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | INTS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.4M |
| IPO Year | 2000 | 2021 |
| Metric | PRSO | INTS |
|---|---|---|
| Price | $0.64 | $4.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 270.3K | 31.7K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.58 | $0.22 |
| 52 Week High | $2.37 | $8.06 |
| Indicator | PRSO | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 66.29 |
| Support Level | $0.60 | $4.50 |
| Resistance Level | $0.92 | $5.00 |
| Average True Range (ATR) | 0.04 | 0.31 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 21.58 | 85.03 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.